S9 Ep10: Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management
Dr Lunning sits down with Jeremy Abramson, MD, of Massachusetts General Hospital, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.
32m Jul 13, 2023
32m
S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.
14m Jul 10, 2023
14m
S9 Ep8: King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer
Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer, findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease, and how the presence or absence of teratoma in the primary tumor should not preclude su...
11m Jul 06, 2023
11m
S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.
13m Jul 03, 2023
13m
S9 Ep6: Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023
Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.
14m Jun 29, 2023
14m
S9 Ep5: Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care
Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.
15m Jun 22, 2023
15m
S9 Ep4: Reuss Reviews the Development of LP-300 in Advanced NSCLC
Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.
10m Jun 19, 2023
10m
S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.
12m Jun 15, 2023
12m
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.
11m Jun 12, 2023
11m
S9 Ep1: Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.
16m Jun 08, 2023
16m
S8 Ep50: Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology
Dr Raskin discusses the road from fellow to fellowship director at Massachusetts General Hospital, the importance of transparency in a program amid increasing emphasis on health and wellness, and the skills a successful program should impart on their trainees.
18m Jun 05, 2023
18m
S8 Ep49: Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML
Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients. 
21m May 29, 2023
21m
S8 Ep48: Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors 
Drs Gottschalk and Krenciute discuss the difficulties of translating successes with CAR T-cell therapy in adults to the pediatric population; ongoing research with investigational products that could reduce T-cell exhaustion, burnout, and the time from bench to bedside; and expectations for the future of cellular therapy in oncology.
24m May 25, 2023
24m
S8 Ep47: Mutale Discusses Disparities in Cancer Clinical Trial Eligibility, Access and Enrollment
Dr Mutale discusses common factors contributing to decreased access to cancer clinical trials, how trial enrollment criteria can affect which groups of patients are underrepresented in these trials, and steps that researchers and clinicians can take to increase diversity in clinical trials and mitigate these disparities. 
14m May 22, 2023
14m
S8 Ep46: Oncology Professionals Explain the Nuances of Career-Building Mentorship and Self-Advocacy
Drs Kovacic, Shaughnessy, Starnes, and Waltz highlight the differences in work culture from their early careers to now, gender-related challenges that persist in medicine today, and advice to incoming medical professionals.
19m May 18, 2023
19m
S8 Ep45: FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant
Dr Horwitz discusses the FDA approval of omidubicel in patients with blood cancers, key efficacy and safety data from the pivotal phase 3 trial, and the benefits omidubicel provides beyond improved neutrophil engraftment.
10m May 15, 2023
10m
S8 Ep44: Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate
Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.
12m May 11, 2023
12m
S8 Ep43: Ehrhardt Explains the Effects of Modifiable Health Conditions on Late Mortality for Childhood Cancer Survivors
Dr Ehrhardt discusses how modifiable chronic health conditions may relate to social determinants of health, noting how these factors can potentially lead to late mortality for survivors of childhood cancer.
14m May 08, 2023
14m
S8 Ep41: Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials
Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to cancer care and research.
40m May 01, 2023
40m
S8 Ep40: Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer
Dr Kim discusses the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma, the rationale for exploring this agent in combination with chemotherapy, and the ongoing HARMONIC trial investigating the combination of LP-300 plus carboplatin and pemetrexed.
9m Apr 27, 2023
9m
S8 Ep39: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating such an active combination regimen into the frontline setting for this population.
19m Apr 24, 2023
19m
S8 Ep38: Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer
Drs Gushchin and Diaz-Montes discuss findings from the HOT trial evaluating health-related QOL outcomes after cytoreductive surgery and HIPEC in patients with primary ovarian cancer, the importance of devising more accurate strategies to assess patient QOL after receiving cytoreduction and HIPEC, and future directions for this research.
12m Apr 20, 2023
12m
S8 Ep37: Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience
Dr Desai discusses the aspects of his oncology fellowship experience that have had the greatest influence on his career growth, the role of mentorship throughout his fellowship and transition to a full-time faculty position, and his advice for current and future oncology fellows.
13m Apr 17, 2023
13m
S8 Ep36: FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer
Dr Gilbert discusses the FDA approval of dostarlimab in patients with endometrial cancer, key efficacy data from the GARNET trial, and how this agent bolsters the endometrial cancer treatment paradigm.
13m Apr 13, 2023
13m
S8 Ep35: Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates
Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.
22m Apr 10, 2023
22m
S8 Ep34: Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management
Drs Mercado and Kovacs discuss the importance of multidisciplinary approaches to lung cancer screening and management, barriers to lung cancer screening that affect how early certain patients are diagnosed with this disease, and where the future of lung cancer detection and treatment is headed.
27m Apr 06, 2023
27m
S8 Ep33: Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer
Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.
17m Apr 03, 2023
17m
S8 Ep32: FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer
Dr Bidard discusses the FDA approval of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, key efficacy and safety data from the EMERALD trial, and the importance of testing for ESR1 mutations in patients with ER-positive, HER2-negative disease.
10m Mar 30, 2023
10m
S8 Ep31: Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration
Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.
43m Mar 27, 2023
43m
S8 Ep29: FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.
8m Mar 20, 2023
8m
S8 Ep28: Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC
Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.
14m Mar 16, 2023
14m
S8 Ep27: Milner, Dalal, and Ligon Discuss Stem Cell Transplant Methods, Results, and Risk Factors in Pediatric Patients
Drs Milner, Dalal, and Ligon discuss hematopoietic stem cell transplant in children with severe aplastic anemia, graft failure risk factors in children receiving hematopoietic cell transplant for non-malignant disorders, and the use of mediports for CAR T-cell infusion.
16m Mar 13, 2023
16m
S8 Ep26: FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.
9m Mar 09, 2023
9m
S8 Ep25: CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
Drs Khushalani, Dietrich, Luke, and Patel discuss the nuances of defining resectability in cutaneous squamous cell carcinoma, the evolving treatment paradigm of resectable disease, and how to translate updated data with cemiplimab into clinical practice.
28m Mar 06, 2023
28m
S8 Ep24: Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma
Dr Jakubowiak discusses interim findings from the ATLAS trial of KRd vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.
23m Mar 02, 2023
23m
S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL
Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.
6m Feb 27, 2023
6m
S8 Ep22: Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management
Dr Mascarenhas discusses established standards of care and ongoing research with JAK inhibitors in patients with myelofibrosis; the available frontline treatment options in this disease; and the nuances of myelofibrosis treatment sequencing.
17m Feb 23, 2023
17m
S8 Ep21: FDA Approval Insights: Zanubrutinib in CLL and SLL
Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
14m Feb 16, 2023
14m
S8 Ep20: Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies
Drs Short and Reagan discuss risk factors that can contribute to patients’ likelihood of developing tumor lysis syndrome, preventive measures for patients most at risk, and the clinical implications of standard treatment options for patients with tumor lysis syndrome.
15m Feb 13, 2023
15m
S8 Ep19: D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, and the importance of establishing a drug’s clinical profile in non–trial target ethnic populations.
10m Feb 09, 2023
10m
S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC
Dr Strickler discusses the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer, key efficacy and safety findings from the MOUNTAINEER trial, and ongoing research seeking to address remaining unmet needs in this population.
10m Feb 06, 2023
10m
S8 Ep18: Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.
14m Feb 02, 2023
14m
S8 Ep17: Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.
11m Jan 30, 2023
11m
S8 Ep17: FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.
13m Jan 26, 2023
13m
S8 Ep16: Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer 
Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy.
13m Jan 23, 2023
13m
S8 Ep15: Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC
Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.
14m Jan 19, 2023
14m
S8 Ep14: Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer
Dr Giacchetti discusses the findings from a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus in breast cancer and how this study highlights the need for further research combining the fields of chronobiology and oncology.
11m Jan 16, 2023
11m
S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL
Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.
12m Jan 12, 2023
12m
S8 Ep12: Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022
Drs Lu, Neven, Jacot, Medford, and Spring highlight updates in the treatment of hormone receptor–positive breast cancer that were presented at the 2022 San Antonio Breast Cancer Symposium.
25m Jan 05, 2023
25m
S8 Ep11: Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates
Dr Oppong discusses findings showing that Black and Hispanic women are more likely than their White counterparts to refuse surgery for nonmetastatic breast cancer, the reasons some patients refuse to undergo surgery, and potential strategies to overcome those objections.
21m Jan 02, 2023
21m